Skip to main content

Table 1 Patient characteristics, clinical TNM stage, and treatment response as determined by RECIST following 2 cycles of therapy

From: A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC

Patient no. Age Gender BMI Stage T N M Histology Cycle 2 RECIST response
1 60 M 27.4 IIB 2b 1 0 Squamous Non-responder (SD)
2 59 F 32.3 IIIA 3 1 0 Squamous Responder (PR)
3 77 M 27.8 IIA 1b 1 0 Adenocarcinoma Non-responder (SD)
4 50 M 25.1 IIIA 3 2 0 Squamous Non-responder (SD)
5 55 M 34.6 IIB 2b 1 0 Squamous Non-responder (SD)
6 33 M 35.9 IIA 2b 0 0 Adenocarcinoma Responder (PR)
7 60 M 29.1 IIIA 1b 2 0 Adenocarcinoma Non-responder (SD)
8 45 F 17.3 IIB 3 0 0 Adenocarcinoma Non-responder (SD)
9 69 F 17.6 IIB 3 0 0 Squamous Responder (PR)